

Additional file 1

## **Combination effects of amino acid transporter LAT1 inhibitor nanvuranlat and cytotoxic anticancer drug gemcitabine on pancreatic and biliary tract cancer cells**

Kou Nishikubo<sup>1</sup>, Ryuichi Ohgaki<sup>1,2</sup>, Xingming Liu<sup>1</sup>, Hiroki Okanishi<sup>1</sup>, Minhui Xu<sup>1</sup>, Hitoshi Endou<sup>3</sup> and Yoshikatsu Kanai<sup>1,2</sup>

<sup>1</sup>Department of Bio-system Pharmacology, Graduate School of Medicine, Osaka University, Osaka, Japan

<sup>2</sup>Integrated Frontier Research for Medical Science Division, Institute for Open and Transdisciplinary Research Initiatives (OTRI), Osaka University, Osaka, Japan

<sup>3</sup>J-Pharma Co., Ltd., Yokohama, Japan

Correspondence

Yoshikatsu Kanai and Ryuichi Ohgaki, 2-2 Yamadaoka, Suita, Osaka 565-0871, Japan.

Email: [ykanai@pharma1.med.osaka-u.ac.jp](mailto:ykanai@pharma1.med.osaka-u.ac.jp), [ohgaki@pharma1.med.osaka-u.ac.jp](mailto:ohgaki@pharma1.med.osaka-u.ac.jp)

TEL: 06-6879-3521

FAX: 06-6879-3529

